The purpose of this study is to examine the role of a well-known and well-tolerated antibiotic, doxycycline, in the treatment of cystic fibrosis patients who are hospitalized. This antibiotic does not effectively treat the bacteria in airways of cystic fibrosis patients, but may reduce the activity of inflammatory molecules in the disease.
One molecule that is inhibited by doxycycline is matrix metalloprotease-9, which is emerging as an important mediator of lung inflammation and damage in cystic fibrosis. We hypothesize that the addition of treatment with doxycycline in CF inpatients will reduce MMP-9 activity and inflammatory markers in the sputum of cystic fibrosis patients compared to CF patients not treated with doxycycline.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
40
100 mg twice a day for 8 days
placebo
University of alabama at Birmingham
Birmingham, Alabama, United States
Number of Adverse Events
Examines tolerability and safety with focus on adverse events (AEs) and serious adverse events (SAEs)
Time frame: 1 month from enrollment
Matrix Metalloprotease-9 (MMP-9) Protein Levels in Sputum
Mean sputum matrix metalloprotease-9 (MMP-9) levels measured at the end of therapy
Time frame: 8 days past baseline
Mean Sputum Matrix Metalloprotease-9 (MMP-9) Activity End of Treatment
Measurement of endogenous active matrix metalloprotease-9 (MMP-9) in the sputum
Time frame: 8 days
Mean Change in Pulmonary Function Over Treatment Duration
Observe change in FEV1% predicted from beginning to end of study
Time frame: Baseline to end of inpatient clinical exacerbation (average 14 days)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.